Physician profile
Lisa C Elder
NPI 1558827287
$17,841.56
in general payments reported to CMS, 2019-2025
38 companies · $5,586 in 2025
The $5,586 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,160 · 2022: $1,706 · 2023: $2,686 · 2024: $2,704 · 2025: $5,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,752 · Travel and Lodging: $1,223 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,751.92 |
| Travel and Lodging | $1,223.20 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,915.17 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Medtronic, INC. | $2,800.24 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $2,328.73 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $1,962.19 | 2021-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,031.69 | 2021-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $863.88 | 2021-2025 | Gvoke Hypopen |
| Insulet Corporation | $857.00 | 2021-2025 | Omnipod |
| Abbott Laboratories | $748.65 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $689.30 | 2021-2025 | Repatha, Evenity, Repatha |
| Cequr Corporation | $528.01 | 2023-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $465.92 | 2021-2024 | |
| Dexcom, INC. | $315.76 | 2021-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $315.51 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $283.24 | 2021-2024 | Farxiga, Lokelma |
| Esperion Therapeutics, INC. | $273.48 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $235.56 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $135.47 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $131.72 | 2021 | |
| Amneal Pharmaceuticals LLC | $126.60 | 2021-2025 | Unithroid |
| Abbvie INC. | $117.79 | 2021-2025 | |
| Zealand Pharma US, INC. | $116.67 | 2022 | |
| Sequel Med Tech, LLC | $84.43 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $70.46 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $58.75 | 2024 | |
| Ibsa Pharma INC. | $55.28 | 2024-2025 | Licart, Tirosint, Flector |
| Amarin Pharma, INC. | $53.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.16 | 2022 | |
| Corcept Therapeutics | $35.67 | 2024 | Korlym |
| Alexion Pharmaceuticals, INC. | $31.09 | 2021 | |
| Bigfoot Biomedical INC | $26.16 | 2023 | Unity Diabetes Management System |
| Kyowa Kirin, INC. | $25.12 | 2023 | Crysvita |
| Glaxosmithkline, LLC. | $20.51 | 2025 | Arexvy, Shingrix |
| Halozyme INC | $18.61 | 2023 | |
| Evoke Pharma, INC. | $14.82 | 2025 | |
| Nevro Corp. | $14.76 | 2023 | Senza |
| Ultragenyx Pharmaceutical INC. | $13.33 | 2021 | |
| Pfizer INC. | $12.75 | 2021 | |
| Radius Health, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.